Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

Antonio Palumbo, Francesca Gay, Patrizia Falco, Claudia Crippa, Vittorio Montefusco, Francesca Patriarca, Fausto Rossini, Simona Caltagirone, Giulia Benevolo, Norbert Pescosta, Tommasina Guglielmelli, Sara Bringhen, Massimo Offidani, Nicola Giuliani, Maria Teresa Petrucci, Pellegrino Musto, Anna Marina Liberati, Giuseppe Rossi, Paolo Corradini, Mario Boccadoro

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the effect of bortezomib as induction therapy before autologous transplantation, followed by lenalidomide as consolidation- maintenance in myeloma patients. Patients and Methods: Newly diagnosed patients age 65 to 75 years were eligible. Induction (bortezomib, doxorubicin, and dexamethasone [PAD]) included four 21-day cycles of bortezomib (1.3 mg/m 2 on days 1, 4, 8, and 11), pegylated liposomal doxorubicin (30 mg/m2 on day 4), and dexamethasone (40 mg/d; cycle 1: days 1 to 4, 8 to 11, and 15 to 18; cycles 2 to 4: days 1 to 4). Autologous transplantation was tandem melphalan 100 mg/m2 (MEL100) and stem-cell support. Consolidation included four 28-day cycles of lenalidomide (25 mg/d on days 1 to 21 every 28 days) plus prednisone (50 mg every other day), followed by maintenance with lenalidomide (LP-L; 10 mg/d on days 1 to 21) until relapse. Primary end points were safety (incidence of grade 3 to 4 adverse events [AEs]) and efficacy (response rate). Results: A total of 102 patients were enrolled. In a per-protocol analysis, after PAD, 58% of patients had very good partial response (VGPR) or better, including 13% with complete response (CR); after MEL100, 82% of patients had at least VGPR and 38% had CR; and after LP-L, 86% of patients had at least VGPR and 66% had CR. After median follow-up time of 21 months, the 2-year progression-free survival rate was 69%, and the 2-year overall survival rate was 86%. During induction, treatment-related mortality was 3%; grade 3 to 4 AEs included thrombocytopenia (17%), neutropenia (10%), peripheral neuropathy (16%), and pneumonia (10%). During consolidation- maintenance, grade 3 to 4 AEs were neutropenia (16%), thrombocytopenia (6%), pneumonia (5%), and cutaneous rash (4%). Conclusion: Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance, is an effective regimen.

Original languageEnglish
Pages (from-to)800-807
Number of pages8
JournalJournal of Clinical Oncology
Volume28
Issue number5
DOIs
Publication statusPublished - Feb 10 2010

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients'. Together they form a unique fingerprint.

Cite this